Dulaglutide - Eli Lilly and Company

Alternative Names: LY-2189265; Trulicity

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Class Antihyperglycaemics; Glucagon-like peptides; Immunoglobulin Fc fragments; Recombinant fusion proteins
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

26 Apr 2023 Eli Lilly completes a phase III clinical trial in Type 2 diabetes mellitus (Combination therapy, Treatment-experienced) in Japan (SC) (NCT04809220)
28 Feb 2023 Eli Lilly has patent protection for dulaglutide in Japan until 2029
26 Jan 2023 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of dulaglutide for the treatment of Type 2 diabetes mellitus (In Adolescents, In children) in European Union

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com